Urologix Secures $2 Million Credit Facility From SVB
Urologix, Inc., a medical device company for in-office procedures to treat BPH that provide safe, durable and effective results, announced that it has secured a $2 million credit facility through Silicon Valley Bank (SVB).
“By securing this line of credit, we gain access to additional funds to support the ongoing integration of Prostiva RF Therapy and to support our continued focus on expanding patient and urologist awareness of the benefits of in-office therapies to treat the symptoms and obstruction associated with BPH,” stated Stryker Warren, Jr., CEO.
Urologix provides urologist customers two proven technologies to treat the widest range of patients suffering from enlarged prostate in the comfort of their office setting, Cooled ThermoTherapy (CTT) and Prostiva RF Therapy.
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH).
Silicon Valley Bank is a bank for technology, life science, cleantech, venture capital, private equity and premium wine businesses.